JERSEY CITY, N.J., May 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovativetherapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel at the 2018 BIO International
About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: email@example.com
Investor RelationsSusan KimArgot PartnersTel: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/scynexis-to-participate-in-a-panel-at-the-2018-bio-international-convention-300652176.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!